A platform patent claims the tool; a product patent claims the cure. US11344609B2 - "Compositions and methods for treating hemoglobinopathies," issued May 31, 2022 to Beam Therapeutics Inc. - sits on the product side, claiming base editing applied to a specific class of blood disorders.
The narrowing limitation is the therapeutic use. Where Harvard's foundational nucleobase-editor claims reach the deaminase-Cas fusion architecture broadly, this Beam grant ties that architecture to treating hemoglobinopathies - the inherited hemoglobin disorders including sickle cell disease and beta-thalassemia. The CPC tags spell it out: C12N 9/78 (deaminase), C12N 5/0641 (blood-cell culture), A61P 7/06 (treating anemias).
Why does a therapeutic-use claim sit downstream of a platform claim? Because the platform owner controls the architecture, and the product developer controls the specific clinical application. Beam's position rests on the use, the target edit, and the cell-engineering method; its freedom to commercialize still has to account for the upstream platform claims it builds on. Use claims and architecture claims coexist as layers.
The claim-construction questions here are concrete: which edit, in which gene, in which cells, for which disorder. A competitor's base-editing therapy for hemoglobinopathy infringes only if it falls within the recited method and target. The breadth of 'hemoglobinopathies' as an indication is exactly the kind of term a challenger would test, and a court would construe, against the specification's enabling examples.
For the landscape, this grant marks the moment base editing crossed from platform to therapy in the patent record. It is the IP correlate of the field's clinical ambition - editing the genome to correct an inherited blood disease - and it shows how a foundational architecture gets carved into protectable product positions one indication at a time.